Login to Your Account

Lively Field Of Enzyme Therapy Promises To Grow Even Hotter

By Randall Osborne

Monday, July 1, 2002
You don't need much, but you better have some or else. The subject is enzymes, replacement therapy for which has been in the forefront in June, with big player Genzyme General Corp. and partner BioMarin Pharmaceuticals Inc. making headlines (good news), as well as competitor Oxford GlycoSciences plc (bad news). (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription